ЛЕЧЕНИЕ ХРОНИЧЕСКИХ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ КИШЕЧНИКА ИММУНОСУПРЕСИВНЫМИ БИОЛОГИЧЕСКИМИ ПРЕПАРАТАМИ



Цитировать

Полный текст

Аннотация

Распространенность, тяжесть течения, сложности лечения хронических воспалительных заболеваний кишечника (ХВЗК) – болезни Крона (БК) и язвенного колита (ЯК) - обусловливают значение этой проблемы в современной гастроэнтерологии. Несмотря на интенсивные исследования, патогенез ХВЗК остается неясным. ХВЗК развиваются вследствие сочетанного воздействия многих неблагопрятных факторов при ведущей роли генетических факторов и факторов внешней среды.

Список литературы

  1. Newman B, Siminovitch KA. Recent advances in the genetics of inflammatory bowel disease. Curr Opin Gastroenterol. 2005; 21: 401-407.
  2. Cashman KD, Shanahan F. Is nutrition an aetiological factor for inflammatory bowel disease? Eur J Gastroenter Hepatol. 2003; 15: 607-613.
  3. Quelette AJ. Defensin-mediated innate immunity in the small intestine. Best Prac Res Clin Gastroenterol. 2004; 18: 405-419.
  4. Eckmann L. Defence molecules in intestinal innate immunity against bacterial infections. Curr Opin Gastroenterol. 2005; 21: 147-151.
  5. Herrlinger K, Stange EF. Chroonisch-entzuendliche Darmerkrankungen – neue Therapieansaetze. Med Klein. 2008; 103: 90-101.
  6. Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007; 56: 453-455.
  7. Lemann M, et al. A randomized, double-blind, controlled withdrawal trial in Crohn´s disease patients in long-term remission on azathioprine. Gastroenterology. 2005; 128: 1812-1818.
  8. Kozarek RA, et al. Methtrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med. 1989; 110: 353- 356.
  9. D´Haens G, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antobodies in Crohn´s disease: a European multicenter trial. 1999. Gastroenterology; 116: 1029-1034.
  10. Hommes DBF, Baert F, Van Assche G, et al. A randomized controlled trial evaluating the ideal medical management for Crohn´s disease: top-down vs. step-up strategies. Gastroenterology. 2005; 128: A577.
  11. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Long-term evolution of disease behavior of Crohn´s disease. Inflamm Bowel Dis. 2002; 8: 244-250.
  12. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosupressants in Crohn´s disease on the need for intestinal surgery. Gut. 2005; 54: 237-241.
  13. Baraliokos X, et al. Radiographic progression in patients with ankylosing spondylitis after 4 years of treatment with the anti-TNF-(alpha) antibody infliximab. Rheumatology (Oxf). 2007; 46: 1450-1453.
  14. Baumgart DC, Tanczos BT, Dignass A. Therapie chronisch entzuendlicher Darmerkrankungen mit Biologika und Immunmdulatoren. DBI. 2006; 26: 144-146.
  15. Tilg H, Moschen A, Kaser A. Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases. Expert Opin Biol Ther. 2007; 7: 1051- 1059.
  16. Targan SR, et al. A short-team study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn´s disease. Crohn´s Disease cA2 Study Group. N Engl J Med. 1997; 337: 1029-1035.
  17. Lemann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroiddependent Crohn´s disease patients: a randoized placebo-controlled trial. Gastroenterology. 2006; 130: 1054-1061.
  18. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn´s disease. Gastroenterology. 2004; 126: 402-413.
  19. Present DH, et al. Infliximab for the treatment of fistulas in patients with Crohn´s disease. N Engl J Med. 1999; 340: 1398-1405.
  20. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulising Crohn´s disease. N Engl J Med. 2004; 350: 876-885.
  21. Jarnerot G, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomoized, placebo-controlled study. Gastroenterology. 2005; 128: 1805-1811.
  22. Rutgeerts P, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 2462-2476.
  23. Ljung T, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm Country. Gut. 2004; 53: 849-853.
  24. Colombel JF, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn´s disease: the Mayo Clinic experience in 500 patients. Gastroenterology. 2004; 126: 19-31.
  25. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19562 patients during 89710 person years of observation. Arthritis Rheum. 2007; 56: 1433-1439.
  26. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serios infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006; 295: 2275-2285.
  27. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn´s disease: the CLASSIC-1 trial. Gastroenterology. 2006; 130: 323-333.
  28. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn´s disease: resalts of the CLASSIC II trial. Gut. 2007; 56: 1232-1239.
  29. Сolombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn´s disease: the CHARM trial. Gastroenterology. 2007; 132: 52-65.
  30. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn´s disease previously treated with infliximab. A randomized trial. Ann Intern Med. 2007; 146: 829-838.
  31. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn´s disease. Gastroenterology. 2005; 129: 807-818.
  32. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintance therapie with certolizumab pegol for Crohn´s disease. N Engl J Med. 2007; 357:239-250.
  33. Zink A, Strangfeld A, Schneider M, et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical tials. Arthritis Rheum. 2006; 54: 3399-3407.
  34. Schreiber S. Morbus Crohn – Infliximab, Adalimumab und Certolizumab-Pegol: Was bringen die neuen Gegenspieler des TNF-a? DMW. 2007; 132: 1770-1774.
  35. Khanna D, McMahon M, Furst D. Safety of tumor necrosis factor alpha antagonists. Drug Safety. 2004; 34: 161-164.
  36. American college of rheumatology: guidelines fort he management of rheumatoid arthritis. 2002, update. Arthritis Rheum. 2002; 46: 328-346.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Шварц В.Я., Ногалле А.М., 2017

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-76803 от 24 сентября 2019 года. 


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах